The authors suggested that the MTAP deficiency frequently observed in osteosarcoma can be targeted with inhibitors of de novo purine synthesis, as a potential chemotherapy strategy for MTAP-negative osteosarcoma patients [43]. The gene discussed is MTAP; the disease is osteosarcoma.